Applications in the Clinic: The Anti-VEGF Aptamer

The Aptamer Handbook: Functional Oligonucleotides and Their Applications

Volumn , Issue , 2006, Pages 443-460

  Realini, Tony ^a   Ng, Eugene W M ^b   Adamis, Anthony P ^b  

^a West Virginia University Eye Institute   (United States)

^b Eyetech Pharmaceuticals Inc   (United States)

Author keywords

Anti VEGF aptamer; Applications; Aptamer handbook; Clinic; Enter macugen; Rationale for targeting VEGF; Vascular endothelial growth factor (VEGF) inhibition; VEGF therapeutic dilemma

Indexed keywords

EID: 84879838337     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527608192.ch19     Document Type: Chapter

References (53)

1. Adamis, A.P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Folkman, J., Yeo, T.K., Yeo, K.T. (1994). Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 118, 445-450.
2. Aiello, L.P., Avery, R.L., Arrigg, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A., Park, J.E. et al. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331, 1480-1487.
3. Ambati, J., Ambati, B.K., Yoo, S.H., Ianchulev, S., Adamis, A.P. (2003). Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48, 257-93.
4. Angiogenesis Foundation. Understanding angiogenesis. List of known angiogenic growth factors. Available from: http://www.angio.org/understanding/content_understanding.html. Accessed on 24 January 2005.
5. Asayama, N., Shimada, H., Yuzawa, M. (2000). Correlation of Indocyanine Green angiography findings and expression of vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Jpn J Ophthalmol 44, 694-695.
6. Ashton, N. (1957). Retinal vascularization in health and disease. Am J Ophthalmol 44, 7-24.
7. Bell, C., Lynam, E., Landfair, D.J., Janjic, N., Wiles, M.E. (1999). Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 35, 533-542.
8. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., Hanahan, D. (2003). Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111, 1287-1295.
9. Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C. et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380, 435-439.
10. De Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N., Williams, L.T. (1992). The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255, 989-991.
11. Dong, L.M., Childs, A.L., Mangione, C.M., Bass, E.B., Bressler, N.M., Hawkins, B.S., Marsh, M.J., Miskala, P., Jaffee, H.A., McCaffrey, L.A., et al. (2004). Health-and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol 138, 91-108.
12. Eyetech Study Group. (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22, 143-152.
13. Eyetech Study Group. (2003). Anti-vascular endothelial growth factor therapy for sub-foveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-986.
14. Feinsod, M., Chambers, W.A. (2004). Trials and tribulations: a primer on successfully navigating the waters of the Food and Drug Administration. Ophthalmology 111, 1801-1806.
15. Ferrara, N., Houck, K., Jakeman, L., Leung, D.W. (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 13, 18-32.
16. Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H.P., Nguyen, T.N., Peers, D., Chisholm, V., Hillian, K.J., Schwall, R.H. (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4, 336-340.
17. Ferrara, N., Gerber, H.P., LeCouter, J. (2003). The biology of VEGF and its receptors. Nat Med 9, 669-76.
18. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med 285, 1182-1186.
19. Frank, R.N., Amin, R.H., Eliott, D., Puklin, J.E., Abrams, G.W. (1996). Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 122, 393-403.
20. Funatsu, H., Yamashita, H., Ikeda, T., Nakanishi, Y., Kitano, S., Hori, S. (2002). Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133, 537-543.
21. Gerber, H.P., Vu, T.H., Ryan, A.M., Kowalski, J., Werb, Z., Ferrara, N. (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5, 623-628.
22. Gragoudas, E.S., Adamis, A.P., Cunningham, E.T., Jr., Feinsod, M., Guyer, D.R., VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351, 2805-2816.
23. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350, 2335-2342.
24. Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D.D., Shalinsky, D.R., Thurston, G., Yancopoulos, G.D., et al. (2004). Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 165, 35-52.
25. Ishida, S., Usui, T., Yamashiro, K., Kaji, Y., Amano, S., Ogura, Y., Hida, T., Oguchi, Y., Ambati, J., Miller, J.W. et al. (2003a). VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198, 483-489.
26. Jin, K.L., Mao, X.O., Greenberg, D.A. (2000). Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal. J Mol Neurosci 14, 197-203.
27. Kerbel, R., Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2, 727-739.
28. Kim I., Ryan, A.M., Rohan, R., Amano, S., Agular, S., Miller, J.W., Adamis, A.P. (1999). Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 40, 2115-2121.
29. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S., Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
30. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V., Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
31. Lopez, P.F., Sippy, B.D., Lambert, H.M., Thach, A.B., Hinton, D.R. (1996). Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 37, 855-868.
32. Machemer, R. Online Journal of Ophthalmology. Image 1658. Available at: http://www.atlasophthalmology.com/bin/atlas?id=115343470-1113861&nav=1658. Accessed on 7 February 2005.
33. Michaelson, I.C. (1948). The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc UK 68, 137-180.
34. Millauer, B., Wizigmann-Voos, S., Schnurch, H., Martinez, R., Moller, N.P., Risau, W., Ullrich, A. (1993). High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72, 835-846.
35. Miller, J.W., Adamis, A.P., Shima, D.T., D'Amore, P.A., Moulton, R.S., O'Reilly, M.S., Folkman, J., Dvorak, H.F., Brown, L.F., Berse, B. et al. (1994). Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145, 574-584.
36. Miller, K.D., Chap, L.I., Holmes, F.A., Cobleigh, M.A., Marcom, P.K., Fehrenbacher, L., Dickler, M., Overmoyer, B.A., Reimann, J.D., Sing, A.P. et al. (2005). Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23, 792-799.
37. Miquerol, L., Langille, B.L., Nagy, A. (2000). Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127, 3941-3946.
38. National Eye Institute (2005). More Americans facing blindness than ever before report released on one of the most-feared disabilities. Available at: website: http://www.nei.nih.gov/news/pressreleases/032002.asp). Accessed on 24 January 2005.
39. Nissen, N.N., Polverini, P.J., Koch, A.E. Volin, M.V., Gamelli, R.L., DiPietro, L.A. (1998). Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 152, 1445-1452.
40. Qaum, T., Xu, Q., Joussen, A.M., Clemens, M.W., Qin W., Miyamoto, K., Hassessian, H., Wiegand, S.J., Rudge, J., Yancopoulos, G.D. et al. (2001). VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42, 2408-2413.
41. Resnikoff, S., Pascolini, D., Etya'ale, D., Kocur, I., Pararajasegaram, R., Pokharel, G.P., Mariotti, S.P. (2004). Global data on visual impairment in the year 2002. Bull WHO 32, 844-851.
42. Rugo, H.S. (2004). Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9(Suppl), 43-49.
43. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S., Dvorak, H.F. (1983). Tumor cells secrete a vascular per meability factor that promotes accumula tion of ascites fluid. Science 219, 983-985.
44. Senger, D.R., Connolly, D.T., Van De, W.L., Feder, J., Dvorak, H.F. (1990). Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50, 1774-1778.
45. Shalaby, F., Rossant, J., Yamaguchi, T.P., Gertsenstein, M., Wu, X.F., Breitman, M.L., Schuh, A.C. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376, 62-66.
46. Shima, D.T., Nishijima, K., Jo, N., Adamis, A.P. (2004). VEGF-mediated neuroprotection in ischemic retina. Invest Ophthalmol Vis Sci 45:E-Abstract 3270.
47. Storkebaum, E., Carmeliet, P. (2004). VEGF: a critical player in neurodegeneration. J Clin Invest 113, 14-18.
48. Tolentino, M.J., Miller, J.W., Gragoudas, E.S., Jakobiec, F.A., Flynn, E., Chatzistefanou, K., Ferrara, N., Adamis, A.P. (1996). Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103, 1820-1828.
49. Tolentino, M.J., Brucker, A.J., Fosnot, J., Ying, G.S., Wu, I.H., Malik, G., Wan, S., Reich, S.J. (2004). Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina 24, 132-138.
50. Wells, J.A., Murthy, R., Chibber, R., Nunn, A., Molinatti, P.A., Kohner, E.M., Gregor, Z.J. (1996). Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 80, 363-366.
51. Wise, G.N. (1956). Retinal neovascularization. Trans Am Ophthalmol Soc 54, 729-826.
52. Witmer, A.N., Vrensen, G.F.J.M., Van Noorden, C.J.F., Schlingemann, R.O. (2003). Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22, 1-29.
53. Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X., Rosenberg, S.A. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349, 427-434.